#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Huntington's disease Renal cancer metastatic Oesophageal squamous cell carcinoma stage II Myxoid liposarcoma Mantle cell lymphoma recurrent Neuroendocrine carcinoma metastatic Retinal artery occlusion T-cell type acute leukaemia Dermatitis Retinal dystrophy Erythema multiforme Pulmonary alveolar haemorrhage Marginal zone lymphoma recurrent Burkitt's lymphoma refractory Amyotrophic lateral sclerosis gene carrier More trials…

    Learn about Rare Diseases

    Familial haemophagocytic lymphohistiocytosis – Trials in Disease Idiopathic pulmonary fibrosis – Life with Disease Factor VIII deficiency Vascular malformation – Diagnostics Pleomorphic leiomyosarcoma – Treatment Pemphigus – Basic Information Focal segmental glomerulosclerosis CADASIL – Treatment Andersen-Tawil syndrome – Basic Information Glomerulonephritis membranous – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dsimc BUDOPRUTUG Thiopental Sodium Specific Nucleic Acid Sna-Papi Candesartan Cilexetil Idecabtagene Vicleucel M1P Dipotassium Salt Camizestrant Tigulixostat Dinutuximab Beta Esk-001 Desflurane RP2 Fosaprepitant Rmc-035 SP16 Varenicline Baxdrostat Gadoquatrane T89 More therapies…

    Learn about Your Condition

    Spondylolisthesis Dermatitis Prostate cancer recurrent Hairy cell leukaemia recurrent Haemodynamic instability Thermal burn Renal cell carcinoma Kidney transplant rejection Essential hypertension Peritoneal sarcoma Optic atrophy Fibrosarcoma Systemic candida Asymptomatic HIV infection Von Hippel-Lindau disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Endometrial cancer recurrent

  • Study on the Safety and Effectiveness of Lurbinectedin and Dostarlimab for Patients with Advanced Endometrial Cancer After Platinum-based Chemotherapy

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    Investigated Drugs:
    • Dostarlimab
    • Lurbinectedin
    Spain

  • Study on Selinexor as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Endometrial cancer metastatic
    • Endometrial cancer
    • Endometrial cancer recurrent
    Investigated Drugs:
    • Selinexor
    Belgium Czechia Germany Greece Italy Spain
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!